Olaris Presenting at SABCS 2021: Identifying Metabolic Biomarkers of Response in Early-Stage Breast Cancer Patients

Olaris presented new data on the identification of metabolic signatures in matched plasma and serum samples associated with tumor proliferation in early-stage breast cancer (eBC) patients treated with Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) at the upcoming San Antonio Breast Cancer Symposium® to be held December 7-10, 2021. The presentation, conducted in collaboration with Dr. Cynthia Ma, Professor of Medicine, Division of Oncology at Washington University in St. Louis, highlights the use of Olaris’ BoR platform to identify metabolic signatures associated with tumor proliferation, an indicator of treatment resistance, in eBC patients treated with CDK4/6i.

December 6, 2021

Olaris Presenting at SABCS 2021: Identifying Metabolic Biomarkers of Response in Early-Stage Breast Cancer Patients